Bayer's $7.25 Billion Roundup Settlement Faces New Legal Objections

Eight years after a California jury found that Monsanto's Roundup weedkiller caused a school groundskeeper's cancer, the legal battle over the world's most widely used herbicide has reached a new inflection point. Bayer's proposed $7.25 billion class action settlement — designed to put the litigation to rest once and for all — is now facing formal objections that call the deal unconstitutional, a competing federal court bid to seize jurisdiction, and a pending U.S. Supreme Court ruling that could render the entire settlement moot [1][2].

The stakes are enormous. More than 125,000 plaintiffs have filed claims alleging that long-term exposure to glyphosate, the active ingredient in Roundup, caused non-Hodgkin lymphoma [3]. Bayer has already spent more than $10 billion settling earlier rounds of cases [4]. The company's market capitalization has fallen from $95 billion at the time of the Monsanto acquisition in 2018 to roughly $46 billion today [5]. And the scientific debate over glyphosate's carcinogenicity remains genuinely unresolved, with major regulatory agencies on opposite sides.

The Settlement: What's on the Table

In February 2026, Bayer announced a proposed $7.25 billion settlement to resolve both current and future Roundup cancer claims [6]. The deal was filed in Missouri's Circuit Court of the City of St. Louis, where Judge Timothy Boyer granted preliminary approval in March [7].

The settlement covers approximately 65,000 active plaintiffs and creates a compensation program for future victims — people who have used Roundup but have not yet been diagnosed with cancer [3][6]. Under the terms, individual payouts range from roughly $10,000 to $165,000, depending on factors like severity of illness and duration of exposure [8]. Class counsel — the attorneys who negotiated the deal on behalf of plaintiffs — have requested $675 million in fees, representing 9.3% of the total fund [8].

Source: Company filings and court records

Data as of May 23, 2026CSV

This $7.25 billion proposal comes on top of the $10.9 billion Bayer agreed to pay in 2020 to resolve approximately 100,000 lawsuits [4], plus an additional $4.5 billion reserve set aside in 2021 for ongoing claims [9]. The cumulative financial exposure now exceeds $22 billion.

The Objections: "Roughshod Over Basic Due Process"

On May 21, 2026, attorneys representing 13 cancer patients filed formal objections in Missouri state court, calling the settlement a "sweetheart deal" that violates the U.S. Constitution [2]. The filing was led by attorney Ashley Keller, who last month argued before the Supreme Court against Monsanto in a separate Roundup case [2].

The objections fall into several categories:

Constitutional and due process concerns. The objectors argue that the Missouri state court lacks jurisdiction to bind citizens of other states. The filing describes the settlement's opt-out procedures as "comically difficult for injured parties to exercise their constitutionally guaranteed option to opt out of these proceedings" [2]. The deadline for opting out is June 4, 2026 [1].

Adequacy of compensation. Critics contend that individual payouts of $10,000 to $165,000 are inadequate for people diagnosed with a life-threatening cancer. By comparison, jury verdicts in individual Roundup trials have reached into the tens or hundreds of millions of dollars — Dewayne Johnson's original 2018 verdict was $289 million before being reduced to $78 million on appeal [10][11].

Attorney fee structure. The $675 million fee request has drawn sharp criticism. Keller stated: "Monsanto and class counsel walked into court hand in hand to ram through a deal that gifts $675 million to class lawyers while leaving present and future cancer victims with a pittance" [8]. The attorneys requesting the fees counter that 9.3% is within established legal benchmarks and reflects 18 months of negotiations [8].

Future claimant protections. The settlement's "futures" subclass would encompass anyone who "saw" anyone using Roundup — a scope the objectors describe as "unconstitutional and unprecedented in the annals of US jurisprudence" [2]. People who currently use Roundup but have not developed cancer would need to affirmatively opt out or lose their right to seek punitive damages in any future lawsuit [12].

Judicial Fireworks: A "Filthy" Deal

The settlement has also drawn extraordinary criticism from a federal judge. U.S. District Court Judge Vince Chhabria, who oversees the nationwide Roundup multidistrict litigation (MDL) in the Northern District of California, called the deal "filthy," "mind-boggling," and "legally problematic" [13].

Chhabria took particular issue with the process. He noted that on the day the settlement was filed in Missouri state court, there was a meeting with the judge that was not transcribed and that nobody outside the parties knew about. Judge Boyer then granted preliminary approval without giving opponents an opportunity to be heard [13].

On May 22, an attorney opposing the settlement filed a notice of removal seeking to transfer the case from Missouri state court to federal court, with the expectation that it would ultimately land before Judge Chhabria's MDL in California [1][13]. This jurisdictional fight adds another layer of uncertainty: if the case moves to federal court, the July 9 final fairness hearing scheduled by Judge Boyer could be delayed or derailed entirely.

The Supreme Court Wildcard

Running in parallel is Monsanto v. Durnell, a case the Supreme Court heard on April 27, 2026, that could reshape the entire litigation landscape [14][15].

The core question: does EPA approval of Roundup's label shield Bayer from state-law failure-to-warn claims? Under the Federal Insecticide, Fungicide and Rodenticide Act (FIFRA), states cannot impose labeling requirements beyond what federal law demands. But another FIFRA provision says EPA's findings during product registration are not legally binding [14].

The case stems from John Durnell's 2019 lawsuit. A Missouri jury found Monsanto liable in 2023 and awarded $1.25 million for failing to warn about cancer risk from glyphosate [15]. If the Supreme Court rules that federal law preempts state failure-to-warn claims, it could effectively eliminate thousands of pending Roundup lawsuits — and potentially make the $7.25 billion settlement unnecessary from Bayer's perspective [14].

During oral arguments, the justices appeared divided. Justices Jackson, Sotomayor, and Kagan pressed Bayer's attorney on whether preemption would prevent states from responding to evolving scientific research. Justices Kavanaugh, Thomas, and Alito did not press Bayer during oral arguments [15]. A ruling is expected by late June or early July 2026.

The Science: Still Contested After a Decade

The legal battles unfold against a backdrop of genuine scientific disagreement about whether glyphosate causes cancer.

In 2015, the International Agency for Research on Cancer (IARC), a branch of the World Health Organization, classified glyphosate as "probably carcinogenic to humans" based on evidence linking it to non-Hodgkin lymphoma [16]. The U.S. Environmental Protection Agency reached the opposite conclusion, finding glyphosate "not likely to be carcinogenic to humans" [16]. Multiple other regulatory bodies, including the European Food Safety Authority, have sided with the EPA's assessment [17].

The disagreement is partly methodological. IARC evaluates whether a substance can cause cancer under any circumstances (hazard assessment), while the EPA evaluates whether it does cause cancer at real-world exposure levels (risk assessment) [16]. These are different questions, and the divergent conclusions reflect that difference as much as any dispute about the underlying data.

Recent research has continued to produce mixed results. A long-term animal study published in June 2025 in Environmental Health found that low doses of glyphosate caused multiple types of cancer in rats [16]. A 2025 literature review found new evidence for an association between glyphosate-based herbicide exposure and increased risk of non-Hodgkin lymphoma [16]. At the same time, large-scale epidemiological studies, including the U.S. Agricultural Health Study, have not found a clear link between glyphosate use and cancer in agricultural workers [17].

Academic research on the topic has surged. Since 2011, more than 9,500 papers on glyphosate and cancer have been published, peaking at 1,490 papers in 2023 [18].

Source: OpenAlex

Data as of Jan 1, 2026CSV

The Financial Toll on Bayer

The Monsanto acquisition has been a financial catastrophe for Bayer by nearly any measure. The company paid $63 billion for Monsanto in June 2018 [5]. Within months, a California jury handed down the Johnson verdict, and the litigation floodgates opened.

Bayer's market capitalization has fallen from approximately $95 billion at the time of acquisition to roughly $46 billion as of May 2026 — a decline of more than 50% [5]. The stock hit a 20-year low in late 2024 [5]. In March 2025, shares plunged another 10% as ongoing U.S. lawsuits prompted the company to consider capital raises [19].

Source: MacroTrends / Company filings

Data as of May 23, 2026CSV

The cumulative litigation costs — over $10 billion in the 2020 settlement, $4.5 billion in additional reserves, and now $7.25 billion in the proposed new settlement — total more than $22 billion, exceeding a third of the original acquisition price [4][9][6]. Analysts have compared the Monsanto purchase to AOL's merger with Time Warner and Bank of America's acquisition of Countrywide as one of the worst corporate deals in modern history [5].

Despite the financial strain, Bayer continues to operate its pharmaceutical and crop science divisions. The company has argued that the proposed settlement provides certainty for both the company and plaintiffs, and that prolonged litigation serves primarily to enrich plaintiff attorneys at the expense of cancer victims who could receive compensation sooner [6].

The Case for the Settlement

Bayer and the attorneys who negotiated the deal argue that the settlement serves plaintiffs' interests in several ways.

First, litigation is slow. The Roundup MDL currently has 3,903 active claims [3], but with approximately 65,000 total plaintiffs, it would take decades for every case to reach trial individually. Many plaintiffs are seriously ill with cancer and may not live to see a verdict. The settlement offers guaranteed compensation within a defined timeframe [6].

Second, trial outcomes are uncertain. While some jury verdicts have been large — the $289 million Johnson verdict, the $87 million Pilliod verdict, a $2.25 billion verdict in January 2024 — defendants have successfully reduced many awards on appeal, and some cases have been lost outright [10][20]. The settlement eliminates that risk for plaintiffs.

Third, the 9.3% attorney fee request is below the typical 25-33% contingency fee in mass tort litigation [8]. Settlement proponents argue this means more money reaches plaintiffs than in traditional individual representation.

Fourth, the Supreme Court's preemption ruling could eliminate failure-to-warn claims entirely. If Bayer wins Monsanto v. Durnell, plaintiffs who rejected the settlement could find themselves with no legal avenue at all [14].

Who Filed the Objections — and What They Want

The formal objections were filed by attorneys from two plaintiff firms representing 13 cancer patients, led by Ashley Keller [2]. Separately, 14 law firms representing nearly 20,000 plaintiffs asked the court in February to delay preliminary approval, requesting at least 60 additional days for review [21].

The objectors are not seeking to end all litigation. Instead, they want:

• The settlement to be rejected or substantially restructured to provide higher individual payouts [2]
• Meaningful opt-out rights, rather than what they describe as "draconian" procedures designed to trap class members [1]
• Protection of future claimants' right to seek punitive damages [12]
• Removal of the case to federal court, where Judge Chhabria has been more skeptical of the deal's terms [13]

No state attorneys general have publicly filed objections to the settlement as of this writing. The opposition has come primarily from plaintiff-side attorneys who believe the deal undervalues their clients' claims.

If the Settlement Collapses

If the $7.25 billion settlement is rejected — whether by the Missouri court, by a federal court after removal, or because the Supreme Court's preemption ruling changes the calculus — the consequences would ripple far beyond Roundup.

The most immediate impact: approximately 65,000 plaintiffs would return to the litigation pipeline. With the MDL currently processing roughly 4,000 active cases, clearing the backlog through individual trials would take many years. Each trial requires months of preparation, expert witnesses, and jury selection. The practical timeline could stretch well beyond a decade [3].

The broader implications involve other mass tort litigations built on similarly contested science. The PFAS multidistrict litigation now encompasses over 9,300 pending lawsuits, with new cases being added at a rate of more than 400 per month [22]. Johnson & Johnson faces more than 55,000 talcum powder lawsuits [22]. Both litigations involve disputes over scientific causation that mirror the glyphosate debate.

A failed Roundup settlement would signal to defendants in those cases that global resolution through class action is unreliable — and to plaintiffs that individual trials remain the better path. That dynamic could extend litigation timelines across the mass tort system, increase costs for both sides, and delay compensation for claimants who are, in many cases, seriously ill.

What Comes Next

The immediate timeline is compressed. The opt-out deadline for the current settlement is June 4, 2026 [1]. The removal motion seeking to transfer the case to federal court is pending. The Supreme Court's ruling in Monsanto v. Durnell is expected by late June or early July [14]. And the final fairness hearing before Judge Boyer is scheduled for July 9 [7].

These events will likely unfold in rapid succession. A Supreme Court ruling in Bayer's favor on preemption could moot much of the litigation. A ruling against Bayer could increase pressure to settle. And the jurisdictional fight between Missouri state court and federal court could determine which judge ultimately decides the settlement's fate.

After eight years and more than $22 billion, the Roundup litigation remains far from resolution. The science is contested, the courts are divided, and the interests of cancer victims, future claimants, attorneys, and one of the world's largest chemical companies remain in direct conflict.